Pfizer cup set! Three big generic giants launch Celebrex

Source: Biovalley December 10, 2014 Pfizer blockhouse! Actavis, Teva and mylan launched Celebrex generics collectively, which is the first batch of Celebrex generics on the market, with specifications of 50mg, 100mg, 200mg and 400mg capsules Celebrex is Pfizer's fourth largest product (after Lyrica, prevnar, Enbrel), with global sales of about $3 billion in 2013 (including $2 billion in the US market) The launch of Celebrex generic drugs by the three major generic giants means that Pfizer has lost another heavy product At present, Pfizer has been trying to strengthen its R & D pipeline, but it seems to be a step behind its competitors in every field In the field of PCSK9 inhibitors, it is predicted that alirocumab jointly developed by Sanofi and partner regeneron is likely to become the first PCSK9 inhibitor in the market, followed by evolocumab of Amgen and bococizumab of Pfizer In the field of tumor immunology, Pfizer is far behind other competitors, including Merck, Bristol Myers Squibb, Roche and AstraZeneca Pfizer recently signed cooperation with Merck in Germany and iteos in Belgium, and began to build its own assets in the field of immune tumor (related reading: one month, two major transactions! At present, Pfizer is experiencing the most severe generic drug damage First, Lipitor, the super "drug king", encountered a patent cliff at the end of 2011, and then Viagra, the magic blue pill ）Patents in various countries have gradually expired, resulting in a rapid market share split by generic drugs, and brand drug sales plummeted The industry believes that this is one of the reasons why Pfizer is frequently engaged in capital market reconnaissance and merger Some analysts said the possibility of Pfizer's return to AstraZeneca could not be ruled out Other analysts believe that Actavis, the world's third-largest generic drug giant based in Switzerland, may be an alternative target for Pfizer's acquisition, despite the recent $66 billion scramble to marry Allergan, a Botox maker About Celebrex: Celebrex is Pfizer's analgesic brand, which can effectively treat a variety of common clinical acute pain: acute trauma/ Tissue damage (such as acute ankle sprain, acute shoulder tendinitis, bursitis), acute chronic pain (such as acute chronic back pain), postoperative pain; it can also effectively treat chronic pain, such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis Celebrex? As a new generation of non steroidal anti-inflammatory and analgesic drugs, can selectively inhibit the production of prostaglandins by inhibiting cyclooxygenase-2 (COX-2), so as to achieve the effects of anti-inflammatory and analgesic In addition to its significant anti-inflammatory and analgesic effects, Celebrex? Does not inhibit the physiological enzyme cyclooxygenase-1 (COX-1), which has gastrointestinal protection ）Compared with traditional NSAIDs, it greatly reduces the risk of gastrointestinal adverse reactions.